Compound Radar

Arrowhead Pharmaceuticals, Inc. (ARWR) Stock Analysis

United States · Healthcare / Biotechnology

Price $85.11
Market cap $12.02B
Next earnings Nov 24, 2026
Entry status Wait

Last updated Sep 8, 2026

Health Check

Last analyzed Sep 7, 2026

45
45/100 Speculative
  • Financial Health 25
  • Profitability 70
  • Business Quality 50
  • Balance Sheet 35
  • Cash Flow 70

Why this rating?

Health 45/100 — Speculative

Strongest Profitability 70/100
Softest Financial Health 25/100
Wait

Entry timing is weak right now. Quality may be fine; the setup is not.

Company overview

Arrowhead Pharmaceuticals, Inc. (ARWR) is a Biotechnology company in the Healthcare sector. Compound Radar rates Arrowhead Pharmaceuticals, Inc. 45/100 (Speculative) due to solid business quality, strong revenue growth, and elevated leverage.

Investment profile

  • Quality Moderate
  • Growth Strong
  • Balance Sheet Stretched

Financial highlights

Valuation

  • Forward P/E -17.62
  • EV/Revenue 17.89

Profitability

  • Revenue Growth 171.0%
  • Operating Margin -226.0%
  • Net Margin -47.8%
  • ROE -55.2%

Financial strength

  • Cash $1.60B
  • Debt $1.38B
  • Net Cash $218.45M
  • Free Cash Flow $156.89M
  • Current Ratio 5.9

Similar companies

Peers in Biotechnology, ranked by Financial Health.

Company Ticker
Price Current price

Latest quoted price for the name. Helps anchor the setup in today’s market level.

Health Entry

View all in Biotechnology →

FAQ

How Compound Radar scores and tracks Arrowhead Pharmaceuticals, Inc. (ARWR).

View Methodology & FAQ →